Your AI-Trained Oncology Knowledge Connection!

Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 : Episode 5

Opinion

Video

July 10, 2024

Existing Challenges for Patients Receiving 3L+ Therapies in mCRC

Author(s):

John Marshall, MD,Al B. Benson III, MD, FACP, FACCC, FASCO

The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.

EP: 1.Overview of Molecular Testing and Barriers in mCRC

EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC

EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202

EP: 4.Exploring Toxicities for Second Line Treatments in mCRC

Now Viewing

EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC

EP: 6.Factors Driving 3L Therapeutic Selection for mCRC

EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial

EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies

EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC

EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR

EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer

Dr Marshall to Panel: Briefly provide comments and perspectives on this patient case.
Dr Marshall to Dr Ciombor: What present challenges exist for patients with mCRC requiring 3L+ therapy?
- With evolving data and latest approvals, have we gotten closer to addressing those challenges and if so, how?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity

Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity

Latest Conference Coverage

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Application of Real-World Evidence in Selecting CAR T in R/R MM

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Existing Challenges for Patients Receiving 3L+ Therapies in mCRC

EP: 1.Overview of Molecular Testing and Barriers in mCRC

EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC

EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202

EP: 4.Exploring Toxicities for Second Line Treatments in mCRC

EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC

EP: 6.Factors Driving 3L Therapeutic Selection for mCRC

EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial

EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies

EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC

EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR

EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer

Newsletter

Latest CME

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Latest Conference Coverage